CD4 and neoplasm: Solitomab, compared to control BiTE®, caused an increase in the production of type 1 cytokines and cytotoxic activity of tumor associated lymphocytes isolated from pleural fluid in CS harboring patients and may increase recruitment as well as activation of CD4 and CD8+ T cells.